Home>Topics>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb BMY

  1. All
  2. Commentary
  3. Headlines
    1. High rate of lymphoma patients respond to Bristol - Myers drug-study

      Headlines

      Sat, 6 Dec 2014

      Dec 6 (Reuters) - Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol - Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday.

    2. Breakthrough Ideas

      Headlines

      Thu, 4 Dec 2014

      According to trials by Bristol - Myers Squibb , 94% of patients ..... immunotherapy drugs, Bristol - Myers Squib’s Yervoy, began selling in ..... this space include Bristol - Myers Squibb , Merck , Roche ), and AstraZeneca, according to a May 2014 analysis of cancer immunotherapy trial spending budgets by Bloomberg ..... sponsored ADR, 5.0% in Bristol - Myers Squibb Co ., 4.4% in Merck

    3. UPDATE 1-FDA declines to approve Bristol - Myers hepatitis drug

      Headlines

      Wed, 26 Nov 2014

      (Adds details on drug, other Bristol - Myers , rival treatments)

    4. FDA declines to approve Bristol - Myers hepatitis drug

      Headlines

      Wed, 26 Nov 2014

      Nov 26 (Reuters) - Bristol - Myers Squibb Co on Wednesday said U.S. regulators had declined to approve use of its experimental daclatasvir drug for hepatitis C, in combination with other antiviral drugs.

    5. RPT- Bristol - Myers immunotherapy shows promise to replace chemo for melanoma

      Headlines

      Mon, 17 Nov 2014

      Nov 16 (Reuters) - Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol - Myers Squibb Co had a much higher survival rate and had other favorable results.

    6. Bristol - Myers immunotherapy shows promise to replace chemo for melanoma

      Headlines

      Sun, 16 Nov 2014

      Nov 16 (Reuters) - Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol - Myers Squibb Co had a much higher survival rate and had other favorable results.

    7. Pharmacyclics Reports Solid 3Q on Strong Imbruvica Sales; Increasing FVE Modestly

      Commentary

      Wed, 5 Nov 2014

      recently announced several collaborations to test Imbruvica with leading immune-oncology products, including Bristol - Myers Squibb 's PD-1 inhibitor, nivolumab, and AstraZeneca's anti-PD-L1 antibody, MEDI4736. While these studies

    8. Lonza Lowers Revenue Guidance in 3Q Update; Shares Remain Overvalued Despite Sell-Off

      Commentary

      Fri, 31 Oct 2014

      its existing biologics manufacturing agreement with Bristol - Myers Squibb . While few details were provided, the deal likely involves the manufacture of one of Bristol ’s immuno-oncology products, which we expect to

    9. Cobimetinib Combo Results are Positive, but Melanoma Landscape Is Becoming More Challenging

      Commentary

      Mon, 29 Sep 2014

      Mekinist/Tafinlar, which is already on the market, and the increasing use of immuno-oncology drugs such as Bristol - Myers Squibb ’s Yervoy and Opdivo and Merck’s Keytruda, we think that the competitive landscape will be challenging

    10. Incyte 2Q Results as Expected; Despite Pipeline Progress Shares Remain Fully Valued

      Commentary

      Thu, 31 Jul 2014

      checkpoint inhibitor MPDL3280A in lung cancer patients. This follows similar deals with AstraZeneca, Merck, and Bristol - Myers Squibb , which are all focused on the potential for synergistic effects with other immuno-oncology products. We believe

    « Prev12345Next »
    Content Partners